Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
563.50 x 1 590.00 x 1
Post-market by (Cboe BZX)
563.16 +13.88 (+2.53%) 04/17/25 [NASDAQ]
563.50 x 1 590.00 x 1
Post-market 563.16 unch (unch) 16:34 ET
Profile for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Regeneron Pharmaceuticals 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 USA

www.regeneron.com Employees: 15,106 P: 914-847-7000

Sector:

Medical

Description:

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Key Statistics

Overview:

Market Capitalization, $K 61,567,460
Enterprise Value, $K 61,063,660
Shares Outstanding, K 109,325
Annual Sales, $ 14,202 M
Annual Net Income, $ 4,413 M
Last Quarter Sales, $ 3,789 M
Last Quarter Net Income, $ 917,700 K
EBIT, $ 3,991 M
EBITDA, $ 4,474 M
60-Month Beta 0.44
% of Insider Shareholders 7.48%
% of Institutional Shareholders 83.31%
Float, K 101,147
% Float 92.52%
Short Volume Ratio 0.44

Growth:

1-Year Return -37.51%
3-Year Return -18.15%
5-Year Return -0.54%
5-Year Revenue Growth 80.61%
5-Year Earnings Growth 79.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 12.07 on 02/04/25
Next Earnings Date 04/29/25 [BMO]
Earnings Per Share ttm 39.70
EPS Growth vs. Prev Qtr -15.60%
EPS Growth vs. Prev Year -2.75%
Annual Dividend Rate, $ 0.88
Annual Dividend Yield 0.16%
Most Recent Dividend 0.880 on 02/20/25
Next Ex-Dividends Date 02/20/25
Dividend Payable Date 03/20/25
Dividend Payout Ratio 0.00%

REGN Ratios

Ratio
Price/Earnings ttm 13.84
Price/Earnings forward 16.79
Price/Earnings to Growth 1.95
Return-on-Equity % 16.32%
Return-on-Assets % 12.76%
Profit Margin % 31.07%
Debt/Equity 0.07
Price/Sales 4.23
Price/Cash Flow 12.02
Price/Book 2.05
Book Value/Share 268.49
Interest Coverage 87.59

REGN Dividends

Date Value
02/20/25 $0.8800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro